NCT06607055 Immunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia
| NCT ID | NCT06607055 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Intercommunal Aix-Pertuis |
| Condition | Pneumonia, Ventilator-Associated |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-10-04 |
| Primary Completion | 2025-09 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this observational study is to show the direct correlation between the occurrence of recurrence of VAP and postagressive immunoparalysis, monitored by HLA-DR rate below litterature-acknowledged threshold, in a well conducted antibiotherapy context, in patient admitted in the Intensive Care Unit. The main questions it aims to answer are: * evaluation of the association between death and persistence of immunoplegia using HLA-DR monitoring * search an association between immunoplegia depth and severity of the initial state of shock * search an association between immunoplegia depth and viral reactivation * compare association of immunoplegia duration and HLA-DR nadir and VAP occurrence Blood samples will be taken from participants to HLA-DR dosage, at the time of inclusion and once a week then.
Eligibility Criteria
Inclusion Criteria: * Patient over 18 years old * Patient admitted in the Intensive Care Unit of the CHIAP * Patient under mechanical ventilation * Patient with infectious pneumonia * Informed Consent Form (ICF) obtained from the patient or emergency ICF obtained from close relatives * Patient beneficiary of French social security, whatever the regime Exclusion Criteria: * Patient under 18 years old * Patient with severe neutropenia (neutrophils \< 0.5 G/L) * Patient under immunosuppressive treatment * Use of corticosteroids (intravenous or oral) prior to ICU admission * Use of therapeutic antibodies * Onco-hematological disease (e.g. lymphoma, leukemia...) under treatment or treated in the 5 years prior to inclusion * End of chemotherapy 6 months prior to inclusion * Patients with innate or acquired immune deficiency (e.g., severe combined immunodeficiency, HIV or AIDS, at any stage) * Patients with a decision to limit or discontinue active therapies, at the time of inclusion * Patien